Phase I trial of HTL-0022562 in healthy volunteers for the treatment of migraine
Latest Information Update: 10 Apr 2024
At a glance
- Drugs HTL 0022562 (Primary)
- Indications Migraine
- Focus Adverse reactions
- Sponsors Nxera Pharma; Sosei
Most Recent Events
- 01 Apr 2024 According to a Nxera Pharma Co., Ltd. media release, Sosei Heptares name changed to Nxera Pharma Co., Ltd.
- 19 Mar 2018 New trial record
- 13 Mar 2018 According to a Sosei media release, earlier the first dosing in the Phase I clinical trial in healthy volunteers was expected in late 2018. Sosei will provide an update about the trial later this year